Athira Pharma (NASDAQ:LONA) Upgraded at Mizuho

Mizuho upgraded shares of Athira Pharma (NASDAQ:LONA) from a neutral rating to an outperform rating in a research report report published on Thursday, Marketbeat reports. The firm currently has $10.00 price target on the stock.

Several other equities research analysts have also recently weighed in on LONA. Weiss Ratings initiated coverage on Athira Pharma in a report on Wednesday, February 11th. They issued a “sell (d-)” rating for the company. Wall Street Zen upgraded Athira Pharma to a “hold” rating in a report on Saturday, February 14th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Athira Pharma presently has an average rating of “Hold” and a consensus price target of $10.00.

Athira Pharma Stock Performance

Shares of Athira Pharma stock opened at $5.56 on Thursday. The company has a market capitalization of $21.93 million, a price-to-earnings ratio of -0.57 and a beta of 2.72. Athira Pharma has a one year low of $2.20 and a one year high of $8.36.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.